跳至主要内容
临床试验/NCT01613313
NCT01613313已完成2 期

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

Zachary Gerut1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2012年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
14
试验地点
1
主要终点
Change in Visible Surface Area of the Lipoma

研究概览

简要总结

The purpose of this research is to evaluate the safest and most effective dose of a Food and Drug Administration (FDA) approved drug (XIAFLEX) in the treatment of lipoma (fatty tumors of varying sizes that occur commonly in the adult population). The fat in the lipoma is like normal fat except that it is enclosed in a balloon-like structure which is made of collagen (fibrous tissue). Treatment of the lipoma with an injection of XIAFLEX (a protein that breaks down collagen fibers) may dissolve the collagen/fibrous strands thereby decreasing the size of the lipoma or removing it.

详细描述

Lipomas are common mesenchymal, benign, fatty tumors of varying sizes that occur in the general adult population. They usually present as painful or annoying lumps that are palpable and often visible in the subcutaneous tissue. Many subcutaneous lipomas are asymptomatic and are removed for non-medical reasons. However, they may cause the subject pain or discomfort or interfere with normal activity.

Spontaneous remission of lipomas has not been reported. A lipoma, once it presents itself, remains there for the lifetime of a person who carries it and may stay small or become larger. Alternative treatments of the lipoma are surgery or liposuction. If a large excision is performed there is the problem of having a very large scar and the accompanying issues of healing a large scar, or possible formation of a hematoma followed by consolidation of the hematoma and the remnants of a mass of scar tissue. This is often painful and more problematic than the original lipoma. liposuction also has the potential for hematoma formation followed by scar mass residual.

To avoid the complications listed above, a non-invasive method of treatment, such as enzyme mediated disassociation of adipose tissue, would be desirable. The primary aim of this study is to perform a step-wise approach in dosing to evaluate the safety and efficacy of clostridium histolyticum as a non-operative treatment for lipoma.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinical history lipoma at least one year and no treatment within last 90 days
  • Lipoma diagnosed as benign
  • Lipoma is a single mass with easily definable edges
  • Lipoma has an area of 2.0 to 17 cm squared
  • Women of childbearing potential must use an acceptable method of birth control

排除标准

  • Lipomas on the head, neck, hand or foot, or female breast
  • Women who are nursing or pregnant
  • Subjects who have participated in any investigational drug trial within 45 days of enrollment in this study
  • Subjects with known allergy to collagenase or any of the inactive ingredients in XIAFLEX
  • Subjects with diabetes or any medical condition that would make the subject unsuitable for enrollment.
  • Subjects having a history of trauma in the area of the lipoma
  • Subjects with a history of connective tissue diseases or rheumatological diseases.
  • Subjects with uncontrolled hypertension
  • Subjects currently receiving or planning to receive anticoagulant medication except for less than 150 mg aspirin daily and over-the-counter nonsteroidal anti-inflammatory drugs) within 7 days before injection of study drug
  • Subjects having the following laboratory abnormalities:
  • ALT/AST greater than 3 times the upper limit of normal
  • Creatinine greater than 2
  • Hemoglobin/hematocrit and WBC outside the normal range

研究组 & 干预措施

Dose #1

Experimental

single injection 0.058 mg Collagenase Clostridium Histolyticum

干预措施: Collagenase Clostridium Histolyticum (Drug)

Dose #2

Experimental

single injection 0.15 mg Collagenase Clostridium Histolyticum

干预措施: Collagenase Clostridium Histolyticum (Drug)

Dose #3

Experimental

single injection 0.29 mg Collagenase Clostridium Histolyticum

干预措施: Collagenase Clostridium Histolyticum (Drug)

Dose #4

Experimental

single injection 0.44 mg Collagenase Clostridium Histolyticum

干预措施: Collagenase Clostridium Histolyticum (Drug)

结局指标

主要结局

Change in Visible Surface Area of the Lipoma

时间窗: Baseline and Six months post injection of study drug

The primary efficacy outcome is the visible surface area of the lipoma measured as the longest dimension (length) times the longest dimension perpendicular to length (width). Visible surface area will be determined by caliper and will be analyzed as the percent change from baseline at the 6-month post injection visit.

次要结局

  • Relative Change in Volume of the Lipoma(Baseline and 6 months post injection of study drug)

研究者

发起方
Zachary Gerut
申办方类型
Indiv
责任方
Sponsor Investigator
主要研究者

Zachary Gerut

Sponsor-Investigator

Gerut, Zachary, M.D.

研究点 (1)

Loading locations...

相似试验